Study to Improve Deployment-Related Asthma by Using L-Citrulline Supplementation (SEALS)
Abstract
The overall goal of this proposal is to determine if L-citrulline can be used to improve asthma control in subjects with deployment-related asthma. We have previously shown that adult patients with poorly controlled asthma have an abnormal regulation of an amino acid called L-arginine and airway nitric oxide (FeNO). In healthy people, nitric oxide is present in amounts that help keep the airways open. However, in some patients with asthma, nitric oxide and L-arginine are often low. Our preliminary data in obese asthmatics show that L-citrulline, which is an amino acid that can be metabolized into L-arginine, improved lung function and asthma control, while increasing the levels of FeNO. Based on this, we hypothesize that an L-citrulline-based drug strategy will normalize nitric oxide metabolism, suppress oxidative inflammatory responses and improve airway function in previously deployed patients with asthma. Our proposal presents a clinical trial approach to treat deployment related asthma patients using L-citrulline as an add-on therapy to improve asthma control. Our results will potentially show that L-citrulline is a safe, tolerable medication that can make a significant impact on the respiratory health of a large segment of our active and veteran population at a reasonable cost.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2022
- Accession Number
- AD1190896
Entities
People
- Cecile Rose
- Fernando Holguin
- Hope Cruse
- Jennifer Bitzan
- Vong Smith
Organizations
- University of Colorado Boulder